Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.47 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9780647 | 0.98 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1PTGS2CXCL8NR1H4 | |
| SCHEMBL4730302 | 0.95 | PTGS2 (0.51) | CYSLTR2CYSLTR1PTGS2CXCL8NR1H4 | |
| SCHEMBL11072836 | 0.91 | SOAT2 (0.49) | CYSLTR2CYSLTR1CNR2CNR1 | |
| SCHEMBL11072831 | 0.91 | SOAT2 (0.49) | CYSLTR2CYSLTR1CNR2CNR1 | |
| SCHEMBL11065929 | 0.88 | SOAT2 (0.49) | CYSLTR2CYSLTR1PTGS1POLBCNR2 | |
| SCHEMBL11065936 | 0.88 | SOAT2 (0.49) | CYSLTR2CYSLTR1PTGS1POLBCNR2 | |
| SCHEMBL11069324 | 0.88 | SOAT2 (0.49) | CYSLTR2CYSLTR1PTGS1POLBCNR2 | |
| SCHEMBL11069327 | 0.88 | SOAT2 (0.49) | CYSLTR2CYSLTR1PTGS1POLBCNR2 | |
| SCHEMBL11069348 | 0.87 | CYP2C9 (0.46) | CYSLTR2CYSLTR1PTGS2CXCL8NR1H4 | |
| SCHEMBL11635283 | 0.86 | POLB (0.46) | CYSLTR2CYSLTR1POLBNAAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1770 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879675-B1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | UNIV DUKE (US) | 2019-11-13 | — | — | EP | claimed |
| US-20180186885-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-05 | — | — | US | claimed |
| WO-2016205566-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016205551-A2 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| JP-2011506455-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| EP-2231147-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009076170-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
| US-20240240255-A1 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | BICYCLETX LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030875-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4392421-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4392422-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-1503746-A1 | PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS | Novartis AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| CN-1578674-A | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | disclosed |
| EP-1501491-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER PAIN | Novartis AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| CN-1575168-A | Combinations comprising selective cyclooxygenase-2 inhibitors | NOVARTIS AG (CH) | 2005-02-02 | — | — | CN | disclosed |
| WO-2003090737-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER PAIN | NOVARTIS AG (CH) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003061645-A1 | PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS | NOVARTIS AG (CH) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240240255-A1 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | NECTIN4, CD274, SIGLEC7 | CYSLTR2 961/4885CYSLTR1 1097/4885PTGS2 4702/4885 |
| US-12030875-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | CYSLTR2 4809/4885CYSLTR1 4795/4885PTGS2 3844/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | CYSLTR2 4157/4885CYSLTR1 4141/4885PTGS2 1209/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYSLTR2 1586/4885CYSLTR1 1090/4885PTGS2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.